XGEVA — Total revenues
Amgen XGEVA — Total revenues decreased by 8.1% to $411.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 27.4%, from $566.00M to $411.00M. Over 3 years (FY 2022 to FY 2025), XGEVA — Total revenues shows relatively stable performance with a 1.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption and effective commercialization of the therapy, while a decrease may signal increased competition from biosimilars or a decline in the product's clinical lifecycle.
Detailed definition
This metric represents the total gross sales generated by the XGEVA product line, a therapeutic agent used for the preve...
Peer comparison
Comparable to revenue metrics for specific oncology or specialty pharmaceutical product lines at peer biotechnology firms.
amgn_segment_xgeva_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $488.00M | $517.00M | $502.00M | $533.00M | $495.00M | $484.00M | $536.00M | $530.00M | $519.00M | $527.00M | $561.00M | $562.00M | $541.00M | $561.00M | $566.00M | $532.00M | $539.00M | $447.00M | $411.00M |
| QoQ Change | — | +5.9% | -2.9% | +6.2% | -7.1% | -2.2% | +10.7% | -1.1% | -2.1% | +1.5% | +6.5% | +0.2% | -3.7% | +3.7% | +0.9% | -6.0% | +1.3% | -17.1% | -8.1% |
| YoY Change | — | — | — | +9.2% | -4.3% | — | +6.8% | -0.6% | +4.8% | +8.9% | +4.7% | +6.0% | +4.2% | +6.5% | +0.9% | -5.3% | -0.4% | -20.3% | -27.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's xgeva — total revenues?
- Amgen (AMGN) reported xgeva — total revenues of $411.00M in Q1 2026.
- How has Amgen's xgeva — total revenues changed year-over-year?
- Amgen's xgeva — total revenues decreased by 27.4% year-over-year, from $566.00M to $411.00M.
- What is the long-term trend for Amgen's xgeva — total revenues?
- Over 3 years (2022 to 2025), Amgen's xgeva — total revenues has grown at a 1.1% compound annual growth rate (CAGR), from $2.01B to $2.08B.
- What does xgeva — total revenues mean?
- The total revenue generated from sales of the XGEVA therapeutic product.